EVALUATION OF N-GLYCOSYLATION PROFILE OF RECOMBINANT BLOOD COAGULATION FACTOR VIIa MOLECULE

DOI: https://doi.org/10.29296/24999490-2020-04-08

O.B. Ustinnikova(1), O.B. Rounova(1), А.А. Movsesyants(1), R.R. Shukurov(2), M.A.Smolov(2), R.A. Khamitov(2), 1-Scientific Centre for Expert Evaluation of Medicinal Products, Petrovsky Blvd, 8/2, Moscow, 127051, Russian Federation; 2-International Biotechnology Center «GENERIUM» LLC, Vladimirskaya Str. 14, Volginskiy, Vladimir Region, 601125, Russian Federation E-mail: [email protected]

Introduction. The specific activity of blood coagulation factor VIIa depends, among other things, on the presence of N-acetylneuraminic acid (sialic acid) and phosphate residues in the molecule. Thus the authenticity of glycosylation profile as one efficacy and safety proofs of drug product is of particular interest. However, the whole variability of posttranslational modifications requires an individual approach to corresponding assessment processed in accordance with the requirements and recommendations of the comparison of biosimilar drug products. Methods. Objects under the study referred as: original drug product NovoSeven, biosimilar drug product Coagil-VII and European reference standard of Human Coagulation Factor VIIa (rDNA) CRS. Two methodological approaches of high-pH-anion-exchange chromatography (HPAEC) and hydrophilic interaction liquid chromatography (HILIC) with fluorescent and mass-spectrometric detection were used for the analysis of oligosaccharide distribution in all factor VIIa molecules. Results. А set of rFVIIa modifications represented basically by complex biantennary oligosaccharides with insignificant part of triantennary structures was established in this study. The most characteristic modification for Coagil-VII biosimilar was complex bisialylated core-fucosylated biantennary group. Conclusion. The evaluation of the N-glycosylation profile of recombinant blood coagulation factor VIIa based on the comparative analysis of biosimilar drug product, original drug product, and CRS standard sample revealed difference in quantitation of N-glycans among with general matching of the majority of peak retention times. Mass-spectrometric detection allowed to carry out a structural interpretation of HPLC data. A biosimilar drug product was used as an example to illustrate the necessity for factory standards certified in a prescribed manner for the further glycan profile authentication.
Keywords: 
Eptacog alpha, glycosylation profile, authenticity, mass spectrometric analysis, standard sample
Список литературы: 
  1. Sutkeviciute I., Mistiniene E., Sereikaite J., Bumelis V. The influence of different glycosylation patterns on factor VII biological activity. Biochimie. 2009; 91: 1123–30.
  2. Jurlander B., Thim L., Klausen N., Persson E., Kjalke M., Rexen P., Jorgensen T., Ostergaard P., Erhardtsen E., Bjorn S. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin. Thromb. Hemost. 2001; 27: 373–84.
  3. Rukovodstvo po biopodobnym biologicheskim lekarstvennym preparatam, soderzhaschim v kachestve dejstvujuschego veschestva belki biotehnologicheskogo proishozhdenija: voprosy kachestva EMEA/CHMP/BWP/49348/2005.
  4. [Rukovodstvo po biopodobnym biologicheskim lekarstvennym preparatam, soderzhashchim v kachestve deystvuyushchego veshchestva belki biotekhnologicheskogo proiskhozhdeniya: voprosy kachestva EMEA/CHMP/BWP/49348/2005 (in Russian)]).
  5. Garmonizirovannoe trehstoronnee rukovodstvo ICH. Spetsifikatsii: Metody ispytanij i kriterii priemlemosti biotehnologicheskih/biologicheskih preparatov. Q6B. 1999.
  6. [Garmonizirovannoe trekhstoronnee rukovodstvo ICH. Spetsifikatsii: Metody ispytaniy i kriterii priemlemosti biotekhnologicheskikh/biologicheskikh preparatov. Q6B. 1999 (in Russian)].
  7. Normativnye pravovye akty v sfere obraschenija lekarstvennyh sredstv v ramkah Evrazijskogo ekonomicheskogo sojuza. T. 3. Pravila provedenija issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo ekonomicheskogo sojuza. M., 2017; 352.
  8. [Normativnye pravovye akty v sfere obrashcheniya lekarstvennykh sredstv v ramkakh Evraziyskogo ekonomicheskogo soyuza. T. 3. Pravila provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza. M., 2017; 352 (in Russian)].
  9. Ceroni A., Maass K., Geyer H., Geyer R., Dell A., Haslam S.M. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J. Proteome Res. 2008; 7: 1650–9.
  10. Ranzinger R., Herget S., von der Lieth C.-W., Frank M. GlycomeDB – a unified database for carbohydrate structures. Nucleic Acids Res. 2011; 39: 373–6.
  11. Klausen N., Bayne S., Palm L. Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography and mass spectrometry. Mol. Biotechnol. 1998; 9: 195–204.
  12. Böhm E., Seyfried B., Dockal M., Graninger M., Hasslacher M., Neurath M., Konetschny C., Matthiessen P., Mitterer A., Scheiflinger F. Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells. BMC Biotechnol. 2015; 15: 87–101.
  13. Ghaderi D., Taylor R., Padler-Karavani V., Diaz S., Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnol. 2010; 28: 863–7.